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Abstract 
Background: Plasmodium falciparum accounts for approximately 60% of malaria cases in Ethiopia and artemether–
lumefantrine has been used as a first‑line treatment for uncomplicated P. falciparum malaria since 2004. The aim of 
this study was to assess the therapeutic efficacy of artemether–lumefantrine (AL) for the treatment of uncomplicated 
P. falciparum malaria in north‑western Ethiopia.
Methods: A 28‑day one‑arm, prospective evaluation of the clinical and parasitological response to the first‑line 
treatment for uncomplicated P. falciparum malaria was conducted in Enfranze Health Centre in accordance with the 
2009 WHO efficacy study guidelines. Patients were treated with a 3‑day course of AL and clinical and parasitological 
parameters were monitored over a 28‑day follow‑up. All data from recruited patients were imported into an electronic 
data base and Kaplan–Meier survival analysis was used for analysing primary [early treatment failures (ETF), late clinical 
failure (LCF), late parasitological failures (LPF), and adequate clinical and parasitological response (ACPR)] and second‑
ary (PCT, GCT and FCT) outcomes.
Results: Eighty patients were enrolled and all of them completed the 28‑day follow‑up period. The PCR‑corrected 
cure rate was 95.0% (95% CI 87.0–98.4%) and there were two ETF, one LCF and three LPF. Two of the LPF were clas‑
sified as re infections by PCR. Seventy three point seven five percent, 91.25 and 95% of patients had cleared their 
parasitaemia by days 1, 2, and 3, respectively, and 75, 91.25 and 96.25% of patients had cleared their fever by days 1, 2, 
and 3. All patients completely cleared their gametocytes by day 7.
Conclusion: The relatively high cure rate, low proportion of patients still positive on day 3 as well as parasite clear‑
ance times in this study would indicate no imminent threat of artemisinin resistance development in the region. 
However, the threat of spreading or de novo development of artemisinin resistance warrants regular monitoring of 
drug efficacy throughout the region.
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Background
Malaria is a disease caused by protozoan parasites of the 
genus Plasmodium and transmitted by female Anoph-
eles mosquitoes. Plasmodium falciparum is by far the 
most important specie, responsible for nearly all severe 
malaria cases [1, 2]. About 198 million cases of malaria 
occurred globally in 2013 and the disease led to 584,000 
deaths. The burden is heaviest in the WHO African 
Region, where an estimated 90% of all malaria deaths 
occur, and in children <5  years of age, who account for 
78% of all deaths [3].
Malaria is the leading communicable disease in Ethio-
pia and an estimated 68% of the population of Ethiopia 
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lives in areas at risk of malaria [4]. In the country, P. fal-
ciparum and Plasmodium vivax are the main species 
accounting for roughly 60 and 40% of malaria cases, 
respectively [5, 6]. Plasmodium falciparum causes severe 
malaria with a case fatality rate of about 10% in hospital-
ized adults and up to 33% in children less than 12 years 
old in Ethiopia [7].
Early diagnosis and prompt treatment is one of the 
main strategies in malaria prevention and control and 
it is also the key to reducing morbidity and prevent-
ing mortality [8]. However, efforts towards controlling 
malaria are greatly challenged by the increasing spread 
of anti-malarial drug resistance [3]. Use of ineffec-
tive anti-malarial drugs contributes to the difficulties in 
reducing malaria morbidity and mortality, leads to the 
spread of malaria to new areas, re-emergence of malaria 
in areas where the disease had been eliminated and it 
has also played an important role in the occurrence and 
severity of epidemics [9]. Anti-malarial drug resistance 
is observed in P. falciparum malaria, but has also been 
identified in P. vivax [10, 11].
In Ethiopia, high level resistance to chloroquine (CQ) 
in 1998 necessitated a change to sulfadoxine–pyrimeth-
amine (SP) as first-line anti-malarial drug. However, 
high treatment failure rates with SP of up to 72% were 
reported in some areas which have led to increasing 
acceptance of using a combination of two or more drugs 
in an attempt to reduce malaria transmission and resist-
ance development. Consequently, artemether–lumefan-
trine (AL) was adopted in 2004, which currently is being 
used as the first-line drug for the treatment of uncom-
plicated P. falciparum malaria [8]. A base-line study in 
2004 showed that AL was a highly efficacious drug with 
a treatment success of 99.1% and with few reports of 
adverse effects [12, 13].
The World Health Organization (WHO) recommends 
artemisinin-based combinations, such as AL, as first-line 
treatment forum complicated P. falciparum malaria in 
all endemic countries [14]. However, resistance of P. fal-
ciparum to artemisinin has been confirmed in western 
Cambodia and Thailand [15]. This resistance has spread 
from the Thai–Cambodia border to the Greater Mekong 
region, up to the border of Myanmar and India [16–19]. 
This resistance has the potential to spread to or develop 
de novo in other parts of the world [20] and drug effi-
cacy may slowly deteriorate over time. The WHO recom-
mends regular monitoring of drug efficacy for the first 
line anti-malarial drugs at defined sentinel sites at least 
once every 2  years in order to detect changes in their 
therapeutic efficacy [14]. The main focus of this study 
was to assess the therapeutic efficacy of AL in the treat-




The study was conducted at Enfranze Health Cen-
tre. Enfranze is a sub-district, located in North Gondar 
administrative zone, Amhara Region, 675  km north of 
Addis Ababa and 60  km from Gondar town and at an 
elevation of 1,500 m above sea level. This area is malaria-
endemic with a total population of about 45,686 (munici-
pality report) and the majority of the population depends 
on subsistence farming.
Study design and period
The design was a one-arm, prospective evaluation of the 
clinical and parasitological response to directly observed 
treatment for uncomplicated P. falciparum malaria con-
ducted between January and May 2013.
Study subjects
The study subjects were recruited among febrile patients 
attending Enfranze Health Centre using inclusion criteria 
as defined in the WHO guidelines for assessing the thera-
peutic efficacy of anti-malarial drugs against P. falcipa-
rum malaria [21].
Inclusion criteria and exclusion criteria
The following inclusion criteria were used for the study: 
mono-infection with P. falciparum, above 6  months of 
age, a parasitaemia of 1,000—100,000/μl, weight >5  kg, 
presence of axillary temperature (≥37.5°C) and no use 
of anti-malarial drugs 2  weeks prior to enrollment into 
the study. Patients with danger signs of severe and com-
plicated malaria according to WHO criteria (including 
severe anaemia defined as haemoglobin <5 g/dl), history 
of allergic reactions to the study drug AL, mixed infection 
with another Plasmodium species, concomitant presence 
of febrile conditions with the potential to confound study 
outcome (e.g. acute respiratory infection, severe diar-
rhoea or other known underlying chronic or severe dis-
eases (e.g. cardiac, renal or hepatic diseases, HIV/AIDS), 
severe malnutrition (defined as a child whose growth 
standard is below −3 z-score, has symmetrical oedema 
involving at least the feet or has a mid-upper arm cir-
cumference <110 mm for 6 month–18 years of age chil-
dren and has a mid-upper arm circumference <170 mm, 
BMI <16 with or has a mid-upper arm circumference 
<180 mm with recent weight loss or underlying chronic 
illness for adults), as well as pregnant and lactating 
women, were not included in the study.
Sample size and sampling technique
The sample size was determined using a single popula-
tion proportion formula according to the WHO guide-
lines: assuming a maximum of 25% clinical failures, 10% 
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precision, and a confidence level of 95% with up to 10% 
losses to follow up a sample size of 80 was calculated [21].
Data collection procedures
A rapid screening procedure was used in an outpatient 
setting to identify patients who meet enrolment cri-
teria. The typical screening data set included age, sex, 
temperature, body weight, pregnancy test, initial blood 
slide examination and haemoglobin. All patients meeting 
the basic enrolment criteria during the screening pro-
cedure were evaluated in greater depth by a member of 
the study team. Physical examination was performed at 
baseline (day 0 before dosing) and on days 1, 2, 3, 7, 14, 
21 and 28. Body weight was determined on day 0 using a 
weight scale. The screening weight was used to calculate 
the dose (number of tablets) to be administered. Axillary 
temperature was measured at baseline (day 0 before dos-
ing) and on days 1, 2, 3, 7, 14, 21 and 28. Female patients 
of child-bearing age (12–49 years) were asked to provide 
a urine sample for pregnancy testing before enrolment in 
the study and if sexually active were provided with con-
doms for the duration of the study.
Sample collection and processing
Finger-prick blood samples were collected from consent-
ing patients for malaria parasite identification and hae-
moglobin level measurement. Patients that satisfied the 
criteria were enrolled into the study and followed up on 
days 1, 2, 3, 7, 14, 21, and 28 where finger-prick samples 
were taken for microscopic glass slides. Another drop of 
blood was collected on Whatman 903® filter paper on day 
0 during enrollment and in case of recurrent parasitae-
mia. The filter paper was air dried and stored in a self-
sealing plastic bag with desiccators for further molecular 
analysis.
Microscopic diagnosis of malaria parasites
Thick and thin blood smears were prepared and stained 
with 10% Giemsa (pH 7.4) for 10  min and read by two 
senior microscopists. Blood films were taken at least 
eight times for each patient during the study period (day 
0, 1, 2, 3, 7, 14, 21 and 28) and during any unscheduled 
visit. A blood film was considered negative when no par-
asites were seen after examining 100 high power fields on 
the thick film. Parasites were counted on thick films rela-
tive to 200 leukocytes by two microscopists blinded to 
each other’s results. Blood smears with discordant results 
(differences between the two microscopists in species 
diagnosis, or differences in parasite density of >50%) were 
re-examined by a third, independent microscopist, and 
parasite density was calculated by averaging the two clos-
est counts.
Genotyping of malaria parasites
In order to differentiate a recrudescence from a newly 
acquired infection, blood spots were collected from all 
patients at day 0 (before drug intake) and in case of LPF 
on Whatman filter paper and sent to Medical University 
of Vienna for genotyping of merozoite surface protein 1 
(MSP1), merozoite surface protein 2 (MSP2) and gluta-
mate-rich protein (GLURP). To exclude mixed infections 
or infections with other human malaria parasites the 
samples were analysed with nested PCR for species clas-
sification as reported previously [22, 23]. Afterwards P. 
falciparum monoinfections were genotyped. Gene loci—
glurp, msp1 and msp2—of these samples were compared 
by PCR as described previously [24].
Haematological assessment
Finger-prick blood samples were used to measure hae-
moglobin. Due to limited resources the actual haemo-
globin concentration should be measured by hemocue. 
However, this study assessed the haematocrit value only. 
In healthy persons, the haematocrit (expressed as a per-
centage) is roughly three times the haemoglobin con-
centration (expressed in grams per decilitre). This ratio 
is maintained in normocytic anaemia, but in most of the 
tropical forms of chronic anaemia the ratio is 3.3:1.
Treatment and follow‑up of patients
All eligible patients were treated with AL (Coartem®) 
(Novartis Pharmaceutical Corporation, Suffern, New 
York, USA for Novartis Pharma AG, Basel, Switzerland, 
and Bach No. F-2832) twice daily on days 0, 1, and 2. 
Study participants were advised to take the study drug 
with milk to improve absorption. Study medication was 
administered based on weight; the first and each morning 
dose were directly observed by the study staff [25]. The 
evening doses were given to the patient/guardian for self-
administration in the presence of health extension work-
ers. Patients were followed for 30  min post-treatment 
and if vomiting occurred, a second full dose was admin-
istered. If repeated vomiting occurred, patients were 
withdrawn from the study. Patients were asked to return 
to the health centre on days 1, 2, 3, 7, 14, 21, and 28 or 
whenever they did not feel well. Patients withdrawn or 
with complications were referred to the health centre for 
proper treatment. Patients experiencing a reemergence 
of P. falciparum parasitaemia were treated with quinine.
In vivo analysis and classification response
Patients were classified as early treatment failure (ETF), 
late clinical failure (LCF), and late parasitological fail-
ure (LPF, adequate clinical and parasitological response 
(ACPR) as per WHO definition [21].
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Data analysis
After checking for completeness all data were imported 
into Excel and Kaplan–Meier survival analysis was used 
for analysing primary (ETF, LCF, LPF, and ACPR) and 
secondary (PCT, FCT, GCT) outcomes, Cox regression 
was used to identify predictor variables of secondary 
outcomes. P values <0.05 were considered statistically 
significant.
Ethical consideration
The study protocol was reviewed and approved by the 
Ethical Review Committee of the School of Biomedi-
cal and Laboratory Sciences, College of Medicine and 
Health Sciences, University of Gondar. Written informed 
consent was obtained from all study participants or their 




A total of 80 patients (46 males and 34 females) were 
enrolled. Baseline demographics are presented in Table 1. 
Not a single participant was lost to follow-up. Headache, 
dizziness, cough, anorexia, and diarrhoea were the most 
commonly reported adverse events in 26, 15, 25, 12 and 
8% of the patients, respectively. Across age groups partic-
ipants had similar median parasite densities, proportion 
of gametocyte carriage and mean temperature (Table 1).
Cure rate of AL against uncomplicated Plasmodium 
falciparum malaria
The PCR-corrected cure rate by Kaplan–Meier analysis 
was 95.0% (95% CI 87.0–98.4%). Two participants devel-
oped ETF on days 2 and 3, respectively. One participant 
had a LCF on day 14 and three participants developed 
LPF on days 21 and 28, respectively, out of which two 
were classified as re-infections based on molecular anal-
ysis of paired samples. The remaining 74 patients com-
pleted the follow-up without recurrence of parasitaemia 
(Table 2).
Effect of treatment with AL on parasite, fever, 
and gametocyte clearance rates
Seventy three point seven five percent, 91.25 and 96.2% 
of patients cleared their parasites by days 1, 2, and 3, 
respectively. The overall mean parasite clearance time 
was 33.6  ±  2.16  h. Seventy five percent, 91.25, and 
97.5% of patients cleared their fever on day 1, 2, and 3, 
respectively. The overall mean fever clearance time was 
33 ±  2.020  h. On day 1, all three patients ≤5  years old 
with gametocytes had cleared their gametocytes where as 
in the five patients >5 years old gametocytes progressively 
decreased and completely cleared by day 7 (Table 3).
Table 1 Demographics of  study participants at  Enfranze 
Health Centre
≤5 years old >5 years old Total
N = 16 N = 64 N = 80
Mean age (SD) 3.61 (0.75) 23.4 (14.9) 19.4 (15.5)
Male no (%) 10 (62.5) 36 (56.3) 46 (57.5)
Mean weight kg 
(SD)
12.9 (1.64) 40.6 (15.6) 35 (17.9)
Mean temp °C 
(SD)









Mean Hgb g/dl 
(SD)
11.6 (1.2) 12.4 (1.8) 12.3 (1.8)
Gametocyte car‑
riage no (%)
3 (18.75%) 5 (7.8%) 8 (10%)
Table 2 PCR uncorrected and  corrected 28  days cure rate 
of AL as well as early and late treatment failures
ETF early treatment failure, LCF late clinical failure, LPF late parasitological failure, 






ETF 0 2 (3.1%) 2 (2.5%)
LCF 1 (6.25%) 0 1 (1.25%)
LPF 1 (6.25%) 2 (3.1%) 3 (3.75%)
ACPR 14 (87.5%) 60 (93.75%) 74 (92.5%)
Cure rate (uncor‑
rected)
14 (87.5%) 60 (93.75%) 74 (92.5%)
Cure rate (PCR‑
corrected)
14 (87.5%) 62 (96.9%) 76 (95%)
Table 3 Proportion of  patients with  parasite, fever and   
gametocyte clearance on days 1, 2, and 3, respectively
D1 day 1, D2 day 2, D3 day 3.
Out come ≤5 years old >5 years old Total
Parasites cleared
 D1 no (%) 12 (75) 47 (73.4) 21 (73.75)
 D2 no (%) 14 (87.5) 59 (92.2) 73 (91.25)
 D3 no (%) 15 (93.75) 61 (95.2) 76 (94.9)
Fever cleared
 D1 no (%) 10 (62.5) 50 (78.1) 60 (75)
 D2 no (%) 13 (81.25) 60 (93.75) 73 (91.25)
 D3 no (%) 14 (87.5) 63 (98.4) 77 (96.2)
Gametocytes cleared
 D1 no (%) 0 2 (40) 2 (25)
 D2 no (%) 0 3 (60) 3 (37.5)
 D3 no (%) 0 3 (60) 3 (37.5)
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Parasite densities and temperature at baseline, parasite, 
fever and gametocyte clearance
Based on parasite density at baseline participants had 
similar mean fever (P = 0.97) and gametocyte (P = 0.798) 
clearance times. There was statistically significant asso-
ciation between parasite density at baseline and mean 
parasite clearance time (P = 0.002) (Table 4).
Based on axillary temperatures at baseline participants 
had similar mean parasite (P = 0.760), fever (P = 0.329) 
and mean gametocyte (P  =  0.498) clearance time 
(Table 5).
Discussion
This study suggests that with a cure rate of around 95% 
AL remains an efficacious treatment for uncomplicated P. 
falciparum malaria in the region. These results are con-
sistent with studies reported from neighboring Kenya, 
96% [25] and Burkina Faso, 96.6% [26] or Togo, 93% [27] 
and slightly lower than previously reported from e.g. 
India, 99.9% [28], Senegal, 100% [29], Congo, 100% [30], 
Tanzania, 100% [31], southern Ethiopia, 99.4% [32] and 
south-western Ethiopia, 97.5% [33]. Most of these results 
are well within the confidence intervals of this study and 
minor differences may be attributable to regional vari-
ations in the duration of deployment of AL before the 
studies were conducted, the age distribution of partici-
pants, levels of prevalence (and, therefore, immunity), 
as well as drug administration practices (e.g. in terms of 
administering with/without food).
Unlike previous reports from south-western Ethiopia 
[33], participants in this study ≤5 years old had a slightly, 
but not significantly (P = 0.18) lower cure rate than those 
>5 years. At least in part this may be attributable to the 
fact that the study explicitly did not interfere with the way 
children are fed and to a low-milk/fat diet typically given 
to children in the study region, which may have caused 
poorer absorption and cure rates in small children.
Unlike most previous studies, in this study there were 
two ETF [32–34]. The two ETF were one male participant 
18 years old with parasite densities of 11,000/µl of blood 
and one male participant 17 years old with parasite den-
sities 10,000/µl. Both had initial parasite densities above 
the mean and were classified as ETF based on develop-
ment of severe malaria day 2 in the presence of parasitae-
mia and parasitaemia on day 3 with axillary temperature 
≥37.5°C.
All except seven participants had cleared parasitaemia 
by day 2. However, four patients (5%; 95% CI 2.0–12.2) 
were still parasitaemic on day 3 (72 h) after initiation of 
treatment. All of these patients had initial parasite counts 
above average and one of them (a 5-year-old female par-
ticipant with 18,000 parasites/µl) later developed a LCF. 
This is considered to be well below the threshold indicat-
ing potentially emerging resistance and is comparable to 
previous findings in southern Ethiopia [32] and Burkina 
Faso [26] and considerably lower than the 21.9% parasi-
taemic patients on day 3 reported from a trial conducted 
in western Cambodia as early as 2007 [15]. With only 
Table 4 Parasite densities at  base line versus  mean parasite, fever and  gametocyte clearance time among  patients 
treated with AL
The statistical tool used to calculate p value is Cox regression.
PCT parasite clearance time, FCT fever clearance time, GCT gametocyte clearance time.
Base line parasite density (no) Mean PCT P value Mean FCT P value Mean GCT P value
≤6,360 (22) 24 30.5 24
6,361–7,675 (18) 24 32 36
7,676–8,743 (20) 26.4 33.6 60
≥8,744 (20) 60 36 60
Total (80) 33.6 0.002 33 0.97 45 0.798
Table 5 Temperature at  base line versus  mean parasite, fever and  gametocyte clearance time among  patients treated 
with AL
PCT parasite clearance time, FCT fever clearance time, GCT gametocyte clearance time.
Temperature at base line (°C) (no) Mean PCT P value Mean FCT P value Mean GCT P value
≤37.8 (22) 30.5 24 –
37.9–38 (20) 37.2 30 32
38.1–38.8 (22) 39.5 38 48
≥38.9 (16) 39 42 60
Total (80) 33.6 0.760 33 0.329 45 0.498
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33.6 h in spite of comparable initial parasite densities the 
parasite clearance times were also considerable shorter 
than those seen in Southeast Asia [35].
Clinical improvement was swift and fever clearance was 
similarly rapid in most of the participants with only three 
participants (3.75%; 95% CI 1.28–10.45) remaining febrile 
up to day 3. Fever clearance largely depends on inclusion 
criteria (e.g. febrile vs. only history of fever) and is, there-
fore, difficult to compare across study sites but seemed 
similar to fever clearance reported in previous studies 
across Africa [26, 30, 36, 37]. All eight participants with 
gametocytaemia on enrollment had cleared their game-
tocytes by day 7. Although this may seem faster than 
some previous reports from Africa, the relatively small 
number does not allow for conclusions of the potential 
influence of AL treatment on malaria transmission.
Conclusion
The relatively high cure rate, low proportion of patients 
still positive on day 3 as well as parasite clearance 
times in this study would indicate no imminent threat 
of artemisinin resistance development in the region. 
Artemether–lumefantrine remains highly efficacious 
in the treatment of uncomplicated falciparum malaria 
in small as well as older children and adults. However, 
the threat of spreading or de novo development of arte-
misinin resistance warrants regular monitoring of drug 
efficacy throughout the region.
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